1. Medtech Insight
  2. >>Business

COVID-19: AdvaMed Asks USTR To Drop Tariffs On More Chinese Medtech Products

The largest medtech industry group has asked the Office of the US Trade Representative to waive tariffs on more medical devices imported from China as the US fights the COVID-19 crisis. AdvaMed wants an indefinite waiver, or at least one that extends a year beyond when the WHO declares an end to the pandemic.

Metaphor image of United States of America and China trade war tariffs as two opposing container cargo and airplane over the port as an economic taxation dispute over import and exports concept

Medical device advocacy group AdvaMed has asked the Trump administration for more Chinese-made products to be excluded from tariffs as the US continues to fight the COVID-19 pandemic.

In March the Office of the US Trade Representative (USTR) announced it was dropping tariffs for a number of medical device products imported from China, including personal protective equipment, in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Medtech Insight

Commission’s Flora Giorgio Says Simplification And Safety Are Key In Evolving EU Regs

 
• By Amanda Maxwell

Predictability, proportionality, stability, harmonization and simplification offer the right way forward to address the challenging unintended effects of the EU medical device regulations, the European Commission’s head of devices tells the EU’s largest annual medtech conference.

German Bionic Launches ‘Strongest Exoskeleton To Date’

 
• By Natasha Barrow

German Bionic’s new exoskeleton Exia helps healthcare practitioners, nurses, and other caregivers to lift and move patients by supporting muscle movement and reducing the risk of injury.

Medtronic Eyes Up to $350M Tariff Hit in FY26, Leans On Cost Controls And Pricing Strategy

 
• By Shubham Singh

Medtronic expects operating profit to grow approximately 7% in fiscal 2026, excluding tariff impacts. If tariffs materialize at the upper end of the projected range, operating profit growth could drop by 2.2 to 3.2 percentage points.